Format

Send to

Choose Destination
J Biotechnol. 2015 Jul 10;205:24-35. doi: 10.1016/j.jbiotec.2015.01.003. Epub 2015 Jan 12.

3D spherical microtissues and microfluidic technology for multi-tissue experiments and analysis.

Author information

1
ETH Zurich, Department of Biosystems Science and Engineering, Bio Engineering Laboratory, Mattenstrasse 26, 4058 Basel, Switzerland.
2
InSphero AG, Wagistrasse 27, 8952 Schlieren, Switzerland.
3
Leibniz Research Centre for Working Environment and Human Factors (IfADo), TU Dortmund University, Ardeystrasse 67, 44139 Dortmund, Germany.
4
KU Leuven, Research Group of Functional Genomics and Proteomics, Naamsestraat 59, 3000 Leuven, Belgium.
5
Leibniz Research Centre for Working Environment and Human Factors (IfADo), TU Dortmund University, Ardeystrasse 67, 44139 Dortmund, Germany; Department of Forensic Medicine and Veterinary Toxicology, Faculty of Veterinary Medicine, South Valley University, 83523 Qena, Egypt.
6
ETH Zurich, Department of Biosystems Science and Engineering, Bio Engineering Laboratory, Mattenstrasse 26, 4058 Basel, Switzerland. Electronic address: olivier.frey@bsse.ethz.ch.

Abstract

Rational development of more physiologic in vitro models includes the design of robust and flexible 3D-microtissue-based multi-tissue devices, which allow for tissue-tissue interactions. The developed device consists of multiple microchambers interconnected by microchannels. Pre-formed spherical microtissues are loaded into the microchambers and cultured under continuous perfusion. Gravity-driven flow is generated from on-chip reservoirs through automated chip-tilting without any need for additional tubing and external pumps. This tilting concept allows for operating up to 48 devices in parallel in order to test various drug concentrations with a sufficient number of replicates. For a proof of concept, rat liver and colorectal tumor microtissues were interconnected on the chip and cultured during 8 days in the presence of the pro-drug cyclophosphamide. Cyclophosphamide has a significant impact on tumor growth but only after bio-activation by the liver. This effect was only observed in the perfused and interconnected co-cultures of different microtissue types on-chip, whereas the discontinuous transfer of supernatant via pipetting from static liver microtissues that have been treated with cyclophosphamide did not significantly affect tumor growth. The results indicate the utility and multi-tissue functionality of this platform. The importance of continuous medium circulation and tissue interaction is highlighted.

KEYWORDS:

Cyclophosphamide; Liver; Pro-drug activation; Tissue engineering; “Body on a Chip”

PMID:
25592049
DOI:
10.1016/j.jbiotec.2015.01.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center